Flamel Technologies S.A.
News and overview for Flamel Technologies S.A.
Flamel Technologies Announces Third Quarter 2009 Results; Additional New Projects; Cash Increases from $45.1 to $48.8 million [Press Release]
Business Wire | 6 days 15 hours 47 minutes ago
Flamel Technologies (Nasdaq:FLML) today announced its financial results for the third quarter of 2009. Highlights in the third quarter included:
Flamel Technologies Announces Licensing Agreement with Pfizer [Press Release]
Business Wire | 18 days 14 hours 47 minutes ago
Flamel Technologies (Nasdaq:FLML) today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel’s Medusa® technology for the development of a controlled release formulation of an already-marketed therapeutic protein. Flamel will receive a further payment of $1 million pursuant to the exercise of the license; Pfizer will pay all development costs of the program, including milestone payments and royalties on any worldwide commercial sales. The program was begun in 2007 with ...
Flamel Technologies Announces Projected Release Date of Third Quarter Results; Conference Call [Press Release]
Business Wire | 18 days 6 hours 32 minutes ago
Flamel Technologies (Nasdaq: FLML) expects to release its financial results for the third quarter of 2009 the morning of November 16th, before the market opening. A conference call to discuss the results has been scheduled for Monday, November 16th, at 8:30 AM (Eastern). A question and answer period is expected to follow the discussion of results.
Reportlinker Adds Nanomedicine Report [Press Release]
PRNewswire | 75 days 14 hours 13 minutes ago
...N.V., Elan Corporation Plc, Elan Drug Technologies, Ensysce Biosciences, Inc., Enzon Pharmaceuticals, Inc., eSpin Technologies, Inc., Flamel Technologies S.A., Johnson & Johnson, Life Technologies...
4 Results
Sign up for AdvaMed SmartBrief
Company Overview
| Company: | Flamel Technologies S.A. |
|---|---|
| Industry: | Drug Delivery Systems |
| Website: | http://www.flamel-technologies.fr |
Flamel Technologies is setting the drug delivery world aflame. The company is using two polymer-based drug delivery systems to develop improved formulations of existing therapies. Its Medusa technology, for injectable drugs, uses an amino-acid polymer to microencapsulate protein peptides and other molecules. Flamel is developing Medusa-enabled versions of long-acting drugs for ailments such as hepatitis C and diabetes. It has also licensed the technology to other drug companies for development of protein drugs. Flamel's second technology, Micropump, is a controlled-release delivery system for small-molecule, orally administered drugs. GlaxoSmithKline's cardiovascular therapy Coreg CR uses the technology.
Key Numbers
| Sales in U.S. Dollars (mil.) | 38.6 (2008) |
|---|---|
| One-year % Growth in Sales | 5.4 (2008) |
| Net Income in U.S. Dollars (mil.) | -12.1 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 284 (2008) |
| One-year % Growth in Number of Employees | -6.0 (2008) |
| Fiscal Year-End | December |